Research Findings on Medicinal Properties of Marijuana
With the passage of initiatives in California and Arizona, the debate about the medical utility of marijuana is in the spotlight once again. On December 30, 1996, the federal government announced that it intends to use its authority to stop doctors from recommending or prescribing marijuana to their patients and is planning a public relations campaign to demonstrate marijuana has no medical value.
The memorandum describing their policy stated that: "a practitioner's action of recommending or prescribing Schedule I substances is not consistent with the 'public interest' (as that phrase is used in the federal Controlled Substances Act) and will lead to administrative action by the Drug Enforcement Administration to revoke the practitioner's registration." Further, a physician who does not have a bona fide doctor patient relationship when recommending or prescribing marijuana will face criminal prosecution.
In addition to threatening doctors for giving medical advice to their patients, the Clinton Administration is undertaking "a public-relations offensive" which will include "a campaign to discredit the notion that smoking marijuana has medicinal benefits." In their December 30 memorandum, the Administration described a public relations effort with medical associations and the public reenforcing the message that marijuana has no medical value. On December 29, 1996 retired General Barry McCaffrey, the nation's "drug czar," claimed in a column syndicated by the Scripps-Howard News Service that "no clinical evidence demonstrate that smoked marijuana is good medicine." He has consistently described medical marijuana as "Cheech and Chong medicine."
The purpose of this report is to provide policy makers, health professionals and the public with the published literature and reports filed with the Food and Drug Administration that demonstrates that doctors have a basis for recommending marijuana as a medicine to their patients.
Marijuana has long been recognized as having medical properties. Indeed its medical use predates recorded history. The earliest written reference is to be found in the fifteenth century B.C., Chinese Pharmacopeia, the Ry-Ya. Between 1840 and 1900, more than 100 articles on the therapeutic use of cannabis were published in medical journals. The federal government in its 1974 report Marihuana and Health states:
The modern phase of therapeutic use of cannabis began about 140 years ago when O'Shaughnessey reported on its effectiveness as an analgesic and anticonvulsant. At about the same time Moreau de Tours described its use in melancholia and other psychiatric illnesses. Those who saw favorable results observed that cannabis produced sleep, enhanced appetite and did not cause physical addiction.
The 1975 report of the federal government began its discussion of medical marijuana by stating: "Cannabis is one of the most ancient healing drugs." The report further noted: "One should not, however, summarily dismiss the possibility of therapeutic usefulness simply because the plant is the subject of current sociopolitical controversy."
The list of medical uses of cannabis from historical references includes:
Many of the symptoms that marijuana historically was used to obtain relief from in these illnesses are symptoms that have been proven to be relieved by marijuana by modern scientific research. This should not be surprising unless we assume that all human experience over thousands of years did not have a factual basis.
As can be seen from the bibliography at the end of this review, there has been a tidal wave of published research demonstrating marijuana's medical usefulness. Indeed, the research studies conducted by various states under FDA protocol state that the research being conducted was in the final phase in anticipation of approval by the FDA. When the federal government stopped research on the medical use of marijuana in 1992 the drug had nearly completed the requirements for new drug approval.
"Drug czar" Barry McCaffrey's assertion in his Scripps-Howard News Service column that "no clinical evidence demonstrates that smoked marijuana is good medicine" is inconsistent with the facts. Whether this is an intentional deception, as part of the federal government's declared public relations offensive against medical marijuana, or whether it is based on ignorance does not matter. The reality is General McCaffrey's statements are not consistent with the facts.
The research studies compiled in this paper include randomized, double-blind, placebo controlled studies, research using a variety of objective and subjective measurements and a range of research protocols. Doctors have a sound basis on which to recommend marijuana for use by their patients. Indeed, physicians are well aware of the medical value of marijuana. In one study, a scientific survey of oncologists found that almost one half (48 percent) of the cancer specialists responding would prescribe marijuana to some of their patients if it were legal. In fact, over 44 percent reported having recommended the illegal use of marijuana for the control of nausea and vomiting.
This paper addresses research that has been published in four areas: cancer, AIDS, glaucoma and muscle spasticity. All of the materials herein were published after 1970. The materials enclosed are either published in peer reviewed journals, government publications or are reports submitted to the federal government by state agencies.
There have been several studies which have been published which focus on the medical value of smoked marijuana and cancer therapy. These include:
The cancer research is relevant to evaluating marijuana as a useful therapy for AIDS patients. The same symptoms are needed to be controlled among AIDS patients: appetite, nausea and vomiting. There have been recent reports of AIDS and marijuana in the literature. A study with THC found relief of nausea and significant weight gain in 70 percent of patients. However, one-fifth of the patients did not like the psychoactive effective of synthetic THC, indicating marijuana is likely to be preferred by AIDS patients. This is consistent with a survey of people with AIDS conducted by a researcher in Hawaii in 1996. The survey found that 98.4 percent of AIDS patients were aware of the medical value of marijuana and 36.9 percent had used it as an antiemetic. Of those who had used it, 80 percent preferred it over prescription drugs including synthetic THC. A study being conducted in Australia of HIV patients found that those who use marijuana had a better quality of life. In particular, those that were HIV positive for over ten years found marijuana to be critical. One patient told the researcher that he considered marijuana to a "saviour."
Regarding glaucoma, there have been significant studies which consistently show that marijuana is effective in lowering intraocular eye pressure. Heightened intraocular eye pressure is the cause of glaucoma. Thus published evidence indicates marijuana preserves the vision of people with glaucoma.
Finally, regarding the control of muscle spasm there is published literature demonstrating marijuana to be effective in controlling convulsions. The control of muscle spasm is important to patients with multiple sclerosis, epilepsy, spinal cord injury, paraplegia and quadriplegia.
In addition to the research published in medical journals, there have been a series of six studies conducted by state health departments under research protocols approved by the U.S. Food and Drug Administration. The focus of these studies, conducted by six state health agencies, was the use of marijuana as an antiemetic for cancer patients. The studies, conducted in California, Georgia, New Mexico, New York, Michigan and Tennessee, compared marijuana to antiemetics available by prescription, including the synthetic THC pill, Marinol®. Marijuana was found to be an effective and safe antiemetic in each of the studies and more effective than other drugs for many patients.
New Mexico: This study involved 250 patients. The study compared marijuana to THC capsules. The research protocol was approved by the FDA in 1978. In order to participate in the research the patient had to have been referred by a physician and had to have been unsuccessful with at least three other antiemetics. Patients were permitted to choose marijuana or the THC pill. Both objective (e.g., frequency of vomiting, amount of vomiting, muscle biofeedback, blood samples and patient observation) and subjective measures were made to determine the effectiveness of the drug.
The study concluded that marijuana was not only an effective antiemetic but also "far superior to the best available conventional drug, Compazine®, and clearly superior to synthetic THC pill." The study found that "[m]ore than ninety percent of the patients who received marijuana ... reported significant or total relief from nausea and vomiting." The study found no major adverse side effects. Only three patients reported adverse reactions, none of these reactions involved marijuana alone. The 1984 report concluded "... the data accumulated over all five years of the program's operation do show that marijuana smoked resulted in a higher percentage of success than does THC ingested."
Michigan: The Michigan research compared marijuana to Torecan®. It involved 165 patients. Upon admission to the program patients were randomized into control groups with some randomized on the conventional antiemetic Torecan® and the remainder randomized to marijuana. When failure on the initial randomized drug occurred, patients could elect to crossover to the alternate therapy. This procedure allowed the Michigan Department of Health to evaluate how well patients responded to both drugs and allowed patients to register their preference.
The Michigan study reported 71.1 percent of the patients who received marijuana reported no emesis to moderate nausea. Ninety percent of the patients receiving marijuana elected to remain on marijuana. Only 8 of 83 patients randomized to marijuana chose to alter their mode of antiemetic therapy. This was almost the inverse of patients randomized to Torecan®, there more than 90 percent -- 22 out of 23 patients -- elected to discontinue use of Torecan® and switched to marijuana.
Very few serious side effects were found related to marijuana use. The most common side effect was increased appetite -- reported by 32.3 percent of patients -- this was a positive effect. The most common negative effects were sleepiness, reported by 21 patients and sore throat, reported by 13 patients.
Tennessee: This study involved an evaluation of 27 patients. The patients had all failed to obtain relief with other forms of antiemetic therapy including oral THC. The study found an overall success rate of 90.4 percent for marijuana inhalation therapy. In comparison it found a 66.7 percent success rate for THC capsules. In the under 40 age group, the study found a 100 percent success rate for marijuana inhalation therapy.
The report concludes:
We found both marijuana smoking and THC capsules to be effective anti-emetics. We found an approximate 23 percent higher success rate among those patients administered THC capsules. We found no significant differences in success rates by age group. We found that the major reason for smoking failure was smoking intolerance; while the major reason for THC capsule failure was nausea and vomiting so severe that patients could not retain the capsule.
New York: In describing the purpose of the marijuana research program the New York Department of Health stated, "[T]he program is a large-scale (Phase III) cooperative clinical trial ..." The central question addressed is "[h]ow effective is inhalation marijuana in preventing nausea and vomiting due to chemotherapy in patients ... who have failed to respond to previous antiemetic therapy?"
By 1985, the New York program had extended marijuana therapy to 208 patients through 55 practitioners. Of that, 199 patients were evaluated. These patients had received a total of 6,044 NIDA-supplied marijuana cigarettes which were provided to patients during 514 treatment episodes.
In percentage terms the results were stunning:
The report concludes, "Patient evaluations have indicated that approximately ninety-three (93) percent of marijuana inhalation treatment episodes are reported to be 'effective' or 'highly effective' when compared to other antiemetics." The New York study reported no serious adverse side effects. No patient receiving marijuana required hospitalization or any other form of medical intervention. See, Evaluation of the Antiemetic Properties of Inhalation Marijuana in Cancer Patients Receiving Chemotherapy Treatment," New York Department of Health, Office of Public Health (Annual Reports).
Georgia: The Georgia program evaluated 119 patients. It compared THC to standardized smoking of marijuana and with patient-controlled smoking. To enter the program a patient had to have failed to obtain relief with on other antiemetics. Patients were randomized to either patient-controlled smoking of marijuana, standardized smoking of marijuana or THC pills.
The report found that both THC and marijuana were effective in providing antiemetic relief for patients who were previously unresponsive to antiemetics. The rate of success was 73.1 percent. Patient controlled smoking of marijuana was successful in 72.2 percent, standardized smoking was successful in 65.4 percent and THC was effective in 76 percent of the cases. In comparing the reasons for failure between marijuana and THC the report found:
The primary reasons for failure of THC capsules were due to either adverse reaction (6 out of 18) or failure to improve nausea and vomiting (9 out of 18). The primary reason for failure of smoking marijuana were due to smoking intolerance (6 out of 14) or failure to improve the nausea and vomiting (3 out of 14).
California: California conducted a series of studies from 1981 through 1989. Annual reports were submitted to the FDA, the state legislature and the Governor. Each year approximately 90 to 100 patients received marijuana. The California research was described as a "Phase III trial."
The study protocol preferred THC pills by making it much easier for patients to enter that portion of the study. Patients who received marijuana had to be over 15 years of age (the THC pill patients had to be over 5 years of age); had to be marijuana experienced, had to use the drug on an inpatient basis (patients could only use marijuana in the hospital and not take the medicine home), and had to be receiving rarely used and severe forms of chemotherapy. Thus the design of the study did not favor marijuana.
Even with this built-in bias against marijuana, the study consistently found marijuana to be an effective antiemetic. In 1981 the California Research Advisory Panel reported, "Over 74 percent of the cancer patients treated in the program have reported that marijuana is more effective in relieving their nausea and vomiting than any other drug they have tried." In 1982, a 78.9 percent effectiveness rate was found for smoked marijuana. By 1983 the panel concluded:
The California Program also has met its research objectives. Marijuana has been shown to be effective for many cancer chemotherapy patients, safe dosage levels have been established and a dosage regimen which minimizes undesirable side effects has been devised and tested.
The California Research Advisory Panel continued to review data on marijuana until 1989 with similar results.
In addition to research on smoked marijuana there has been a host of research on constituents of marijuana. This research is also relevant in measuring the effectiveness of marijuana.
The drug for which there has been the most research is the THC pill. This pill contains pure delta-9-tetrahydrocannabinol in sesame seed oil. This substance is now scheduled in Schedule II of the Controlled Substances Act. When the drug was rescheduled the Food and Drug Administration acknowledged, "The effects of pure THC are essentially similar to those of cannabis containing THC in equivalent amounts." Thus, the federal government has acknowledged that THC, which is available as a medicine, adequately emulates the effectiveness to marijuana. In fact, the research described above shows that marijuana is in fact a more effective medicine than the THC pill.
The research which compares marijuana to the THC pill found that patients preferred marijuana to THC and that marijuana was more effective at treating symptoms. State studies in Michigan and New Mexico found that most patients who tried THC chose to use marijuana instead. The most common reasons for this choice was because THC was more psychoactive, erratic and unpredictable. Patients found they had more control and a quicker response with smoked marijuana than with oral THC. Patients found it difficult to swallow the pill when they were nauseous. Patients were also able to limit their use of marijuana to only the amount needed when it was smoked. For many cancer and AIDS patients this can involve smoking a very small quantity of the drug. With the THC pill the patient must ingest the whole pill and therefore cannot control the dose.
The Chang study published in The Annals of Internal Medicine found that marijuana had a more consistent effect than the oral THC pill. As they note this was consistent with the observations of Sallan and his colleagues in their study published in The New England Journal of Medicine. Alfred Chang et al. stated:
Sallan and his co-workers considered inadequate drug absorption as a possible contributing factor to the lack of antiemetic response seen in some patients. We concur, since THC plasma concentrations appeared to be causally related to an antiemetic response in our study. To avoid this problem, we switched patients to the inhalation route of drug administration when vomiting occurred. Inhaled marijuana results in the same psychological effects as orally administered THC. In our patient populations, smoked THC was more reliable than oral THC in achieving therapeutic blood concentrations.
A final reason why marijuana cigarettes are superior to the THC pill for many patients is that delta-9-THC is not the only marijuana constituent which provides positive medical effects. The bibliography includes research involving such components of marijuana, including various cannabinoids and delta-8-THC. This research indicates that other components of marijuana have beneficial medical effects. Smoking marijuana provides the patient with the benefits of the combination of marijuana's active ingredients in contrast to the effects of THC only.
There is strong scientific evidence that marijuana is a safe and effective medicine. The voters in California and Arizona have recognized this at the ballot box. It is time for the federal government to help resolve this problem rather than threaten doctors with sanctions for providing medical advice to their patients and denying seriously ill patients access to a much needed medicine.
The California and Arizona initiatives, as well as laws in two dozen states, provide an opportunity to resolve the medical marijuana problem. Research on the safety and effectiveness of marijuana is in its final phase. All that is needed is late-Phase III research. These are broad-based research studies which result in large numbers of patients receiving marijuana.
The federal government, in its policy announcement of December 30, stated that it wanted to ensure the integrity of the drug approval process. Part of their plan to do so includes reviewing the research and seeking to fill gaps in research with new research.
Combining the Food and Drug Administration's need for late-Phase III research before it approves marijuana as a medicine, with the decision of voters in California and Arizona to make marijuana medically available, will satisfy two needs. The FDA can make marijuana available to large numbers of people under a research umbrella. (In the early 1980s nearly 1,000 patients a year were using marijuana medically under federally approved research programs. In fact, in one year California requested one million medical marijuana cigarettes from the FDA.) In addition, the FDA could resolve the medical marijuana problem by making marijuana available as a medicine by prescription.
The Food and Drug Administration should contact the health departments of Arizona, California and other states which have expressed interest in medical marijuana and ask them to participate in the final Phase III studies needed to complete the new drug application process. Obtaining results from this research should take less than one year. If they are consistent with previous research it should result in marijuana becoming a prescription drug under Schedule II of the Controlled Substances Act. Such a process will restore the integrity of the medical scientific process of drug approval which has been undermined by the use of medical marijuana as a political tool by those favoring expanded drug war policies.
By taking a constructive approach, rather than a confrontational one, the federal government avoids conflict with state law, does not intrude on the doctor-patient relationship and ensures that, in the end, marijuana is only made available as a prescription medicine to the seriously ill. Arizona and California have presented an opportunity to resolve an issue that is long overdue for resolution.
Beaconsfield, D., Ginsburg, J., and Rainsbury, R. (1973). Therapeutic potential of marihuana. New England Journal of Medicine 289, 1315.
Therapeutic Aspects. (1974). Marijuana and Health, Fourth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 134-143.
Therapeutic Aspects. (1975). Marijuana and Health, Fifth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 117-132.
Bhargave, H. (1978). Potential therapeutic application of naturally occurring and synthetic cannabinoids. General Pharmacology, 9, 195-213.
Ungerleider, J. (1979). Marijuana as a good medicine: Its uses against disease. Lecture delivered to UCLA Center for the Health Sciences, (August 21, 1979).
Zinberg, N. (1979). On cannabis and health. Journal of Psychedelic Drugs, 11, 135-144.
AMA Council on Scientific Affairs. (1980). Marihuana reexamined: Pulmonary risks and therapeutic potentials. Connecticut Medicine, 44, 521-523.
Cohen, S. (1980). Therapeutic aspects. National Institute on Drug Abuse Research Monograph, No. 31, 199-216.
Council on Scientific Affairs. (1981). Marijuana: Its health hazards and therapeutic potentials. Journal of the American Medical Association, 246, 1823-1827.
DuQuesne, J. (1981). Cannabis and the Rule of Law. Lancet, (Sept. 12, 1981), 581.
Rose, M. (1981). Cannabis and the rule of law. Lancet, (July 18, 1981).
Therapeutic potential and medical uses of marijuana. (1982). Marijuana and Health, Institute of Medicine, 139-155.
Schurr, A. (1985). Marijuana: Much ado about THC. Comparative Biochemistry and Physiology, 80 C, 1-7.
Ungerleider, J. and Andrysiak, T. (1985). Therapeutic issues of marijuana and THC. International Journal of Addictions, 20, 691-699.
Grinspoon, L. and Bakalar, J. (1995). Marihuana as Medicine, A Plea for Reconsideration. Journal of the American Medical Association, 273, 1875-1876.
Hollister, L. (1970). Hunger and appetite after single doses of marihuana, alcohol and dextroamphetamine. Clinical Pharmacology and Therapeutics, 12, 44-49.
Sallan, S.E., Zinberg, N.E., and Ferei, E., III. (1975). Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England Journal of Medicine, 293, 795-797.
Greenberg, I., Kuehnle, J., Mendelson, J.H., and Bernstein, J.G. (1976). Effects of marihuana use on body weight and caloric intake in human. Journal of Psychopharmacology (Berlin) 49, 79-84.
Harris, L. (1976). Analgesic and antitumor potential of the cannabinoids. The Therapeutic Potential of Marijuana. (Cohen and Stillman, eds.), 299-309.
Harris, L., Munson, A., and Carchman, R. (1976). Antitumor properties of cannabinoids. The Pharmacology of Marihuana (Braude and Szara, eds.), 749-762.
Chang, A. et al. (1979). Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. Annals of Internal Medicine, 91, 819-824.
Sallan, S.E., Cronin, C. Zelen, M., and Zinberg, N.E. (1980). Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of Medicine, 302, 135-8.
California State Reports, Therapeutic Cannabis Program. Annual Report to the Governor and Legislature, California Research Advisory Panel (1980-1989).
Bateman, D.C. and Rawlins, M. (1982). Therapeutic potential of cannabinoids. British Medical Journal, 284, 1211-1212.
Cannabinoids for nausea. (1981). Lancet, (Jan. 31, 1981), 255-256.
Frytek, S. and Moertel, C.G. (1981). Management of nausea and vomiting in the cancer patient. Journal of the American Medical Association, 245, 394-396.
Neidhart, J., Gagen, M., Wilson, H., and Young, D. (1981). Comparative trial of the antiemetic effects of THC and haloperidol. Journal of Clinical Pharmacology, 21, 385-425.
"Michigan Department of Public Health Marijuana Therapeutic Research Project, Trial A 1980-81," Department of Social Oncology, Evaluation Unit, Michigan Cancer Foundation (March 18, 1982).
Ungerleider, J., Andrysiak, T., Fairbanks, L., Goodnight, J., Sama, G. and Jamison, K. (1982). Cannabis and cancer chemotherapy: A comparison of oral delta-9-THC and prochlorperazine. Cancer, 50, 636-645.
Sensky, T., Baldwin, A., and Pettingale, K. (1983). Cannabinoids as antiemetics. British Medical Journal, 286, 802.
Kutner, Michael H., "Evaluation of the Use of Both Marijuana and THC in Cancer Patients for the Relief of Nausea and Vomiting Associated with Cancer Chemotherapy After Failure of Conventional Anti-Emetic Therapy: Efficacy and Toxicity" as prepared for the Composite State Board of Medical Examiners, Georgia Department of Health, by physicians and researchers at Emory University, Atlanta, (January 20, 1983).
"Annual Report: Evaluation of Marijuana and Tetrahydrocannabinol in the Treatment of Nausea and/or Vomiting Associated with Cancer Therapy Unresponsive to Conventional Anti-Emetic Therapy: Efficacy and Toxicity," Board of Pharmacy, State of Tennessee, July 1983.
"The Lynn Pierson Therapeutic Research Program," the Behavioral Health Sciences Division, Health and Environment Department, State of New Mexico, (March 1983 and 1984).
Vinciguerra, V., Moore, T., and Brennab, E. (Oct. 1988). Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State Journal of Medicine, 525-527.
Doblin, R. and Kleiman, M. (1991). Marijuana as antiemetic medicine: A survey of oncologists' experiences and attitudes. Journal of Clinical Oncology, 9: 7, 1314-1319.
Abrams, D. (1995). Marijuana, the AIDS Wasting Syndrome, and the U.S. Government (Response to Letter) New England Journal of Medicine, Vol. 333 (10): 670-671.
Grinspoon, L.J. and Doblin, R. (1995). Marijuana, the AIDS Wasting Syndrome, and the U.S. Government (Letter to Editor). New England Journal of Medicine, Vol. 333(10): 670-671.
Wesner, B. (1996). The Medical Marijuana Issue Among PWAs: Reports of Therapeutic Use and Attitudes Toward Legal Reform. Drug Research Unit, Social Science Research Institute, University of Hawaii at Manoa.
Hepler, R. and Frank, I., (1971). Marijuana smoking and intraocular pressure. Journal of the American Medical Association, 217, 1932.
Hepler, R., Frank, I. and Ungerleider, J. (1972). Pupillary constriction after marijuana smoking. American Journal of Ophthalmology, 74, 1185-1190.
Shapiro, D. (1974). The ocular manifestations of the cannabinoids. Opthalmologica, 168, 366-369.
Hepler, R. and Petrus, R. (1976). Experiences with administration of marijuana to glaucoma. The Therapeutic Potential of Marijuana. (Cohen and Stillman, eds.), 63-75.
Perez-Reyes, M., Wagner, D., Wall, M. and Davis, K. (1976). Intravenous administration of cannabinoids and intraocular pressure. The Pharmacology of Marihuana (Braude and Szara, eds.), 829-832.
Goldberg, I., Kass, M., and Becker, B. (1978-1979). Marijuana as a treatment for glaucoma. Sightsaving Review, (Winter issue), 147-154.
Crawford, W. and Merritt, J. (1979). Effects of tetrahydrocannabinol on arterial and intraocular hypertension. International Journal of Clinical Pharmacology and Biopharmacy 17, 191-196.
Merritt, J., Crawford, W., Alexander, P., Anduze, A., and Gelbart, S. (1980). Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology, 87, 222-228.
Merritt, J., McKinnon, S., Armstrong, J., Hatem, G., and Reid, L. (1980). Oral delta-9-tetrahydrocannabinol in heterogenous glaucomas. Annals of Ophthalmology, 12, No. 8.
Zimmerman, T. (1980). Efficacy in glaucoma treatment p-- the potential of marijuana. Annals of Ophthalmology, 449-450.
Green, L. (1984). Marijuana effects on intraocular pressure, Applied, Pharmacology in the Medical Treatment of Glaucomas, (S.M. Drance, ed.), 507-526.
Merritt, J. et al. (1981). Effects of topical delta-9-tetrahydrocannabinol on intraocular pressure in dogs. Glaucoma, (Jan./Feb.), 13-16.
Merritt, J., Perry, D., Russell, D., and Jones, B. (1981). Topical delta-9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Journal of Clinical Pharmacology, 21, 467S-471S.
Merritt, J., Olsen J., Armstrong, J., and McKinnon, S. (1981). Topical delta-9-tetrahydrocannabinol in hypertensive glaucomas. Journal of Pharmacy and Pharmacology, 33, 40-41.
Merritt, J. (1982). Glaucoma, hypertension, and marijuana. Journal of the National Medical Association, 74, 715-716.
Merritt, J., Cook, C., and Davis, K. (1982). Orthostatic hypotension after delta-9- tetrahydrocannabinol marihuana inhalation. Ophthalmic Research 14, 124-128.
Merritt, J. et al. (1982). Topical delta-8-tetrahydrocannabinol as a potential glaucoma agent. Glaucoma, 4, 253-255.
Merritt, J. (1984). Outpatient cannabinoid therapy for heterogenous glaucomas: Guidelines for institution and maintenance of therapy. Marijuana '84: Proceedings of the Oxford Symposium on Cannabis, 681-683.
Merritt, J., Shrewsbury, R., Locklear F., Demby, K., and Wittle, G. (1986). Effects of delta-9-tetrahydrocannabinol and vehicle constituents on intraocular pressure in normotensive dogs. Research Communication in Substances of Abuse, 7, 29-35.
Carlini, E., Leite, J., Tannhauser, M., and Berardi, A. (1973). Cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents. Journal of Pharmacy and Pharmacology, 25, 664-665.
Karler, R., Cely, W., and Turkanis, S. (1973). The anticonvulsant activity of cannabidiol and cannabinol. Life Sciences, 13, 1527-1531.
Dunn, M. and Davis, R. (1974). The perceived effects of marijuana on spinal cord injured males, Paraplegia, 12, 175.
Turkanis, S., Cely, W., Olsen, D., and Karler, R. (1974). Anticonvulsant properties of cannabinol. Research Communication in Chemical Pathology and Pharmacology, 8, 231-246.
Consroe, P., Wood, G., and Buchsbaum, H. (1975). Anticonvulsant nature of marijuana smoking. Journal of the American Medical Association, 234, 306-307.
Karler, R. and Turkanis, S. (1976). The antiepileptic potential of the cannabinoids. The Therapeutic Potential of Marijuana, (Cohen and Stillman, eds.), 383-396.
Feeney, D.M. (1979). Marihuana and epilepsy: paradoxical anticonvulsant and convulsant effects. Marijuana Biological Effects: Analysis, Metabolism, Cellular Responses, Reproduction and the Brain, (Nahas, GG., Paxton, M., Bruade, J.C., Hardillier, and Harvey, D.J. eds.) Pergamon Press, Oxford, England, 643-657.
Petro, D. (1980). Marihuana as a therapeutic agent for muscle spasm of spasticity. Psychosomatics, 21, 81-85.
Cunha, J. et al. (1980). Chronic administration of cannabidiol to health volunteers and epileptic patients. Pharmacology, 21, 175-185.
Petro, D. and Ellenberger, C., Jr. (1981). Treatment of human spasticity with delta-9- tetrahydrocannabinol. Journal of Clinical Pharmacology, 21, 413S-416S.
Sandyk, R., Consroe, P., Stern, L., and Snider, S. (1986). Effects of cannabidiol in Huntington's Disease. Neurology, 36, 331.
Hanigan, W.C., Destree, R., and Truong, X.T. (Feb. 1986). The effect of delta-9- tetrahydrocannabinol on human spasticity. Clinical Pharmacology and Therapeutics, 198.
Truong, X.T. and Hanigan, W.C. (Feb. 1986). Effect of delta-9-tetrahydrocannabinol on EMG measurements in human spasticity. Clinical Pharmacology and Therapeutics, 232.
Cannabis. (1986). Therapeutic Claims in Multiple Sclerosis, Int'l Federation of Multiple Sclerosis Societies, 226.
Ames, F. and Cridland, S. (1986). Anticonvulsant effects of cannabidiol. South African Medical Journal, 69, 14
Ungerleider, T. (1987). Delta 9 THC in treatment of spasticity associated with marijuana. Advances in Alcohol and Substance Abuse, 7, 39-51.
Meinck, H.M., Schonle, P.W., and Conrad, B. (1989). Effect of Cannabinoids on Spasticity and Ataxia in multiple sclerosis. Journal of Neurology, 236, 120-122.
Maurer, M., Henn, V., Dittrich A., and Hoffman, A. (1990). Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. European Archives of Psychiatry and Clinical Neuroscience, 240, 1-4.
MOST OF THESE DOCUMENTS CAN BE OBTAINED BY CONTACTING: Kevin B. Zeese, Common Sense for Drug Policy, 3619 Tallwood Terrace, Falls Church, VA 22041, Tel: (703) 354-5694, Fax: (703) 354-5695, email@example.com. *
 Proposition 215 in California creates a defense to criminal charges if the conduct is with marijuana for or possessed by a person who is seriously ill and a physician has recommended the medical use of marijuana to that person. Proposition 200 in Arizona, among other things, allows a doctor to prescribe a Schedule I drug for the treatment of a seriously ill person if it is supported by another doctor and the medical literature.
 Statement Released by Barry McCaffrey, Director of the Office of National Drug Control Policy (ONDCP), The Administration's Response to the Passage of California Proposition 215 and Arizona Proposition 200, December 30, 1996, page 2. See 21 U.S.C. 824(a)(4).
 Tim Golden, "U.S. Government to Prosecute Doctors Who Prescribe Marijuana," New York Times, December 23, 1996.
 Statement Released by Barry McCaffrey, Director of the Office of National Drug Control Policy, The Administration's Response to the Passage of California Proposition 215 and Arizona Proposition 200, December 30, 1996, page 6.
 "Drug czar" McCaffrey has consistently claimed there is no research showing smoked marijuana works. On CNN on December 30 at 1:04 EST, he was asked if there is any evidence that marijuana is an effective medicine. McCaffrey responded, "No, none at all. There are hundreds of studies that indicate that it isn't." This claim is so preposterous that the drug czar's employees will not even support it. On January 2, a spokesperson for McCaffrey's office denied her boss had ever made such a claim. On CNN's "Burden of Proof," Patricia Seitz, General Counsel, ONDCP, said, "He has not said there is no research. He has not said there is no research."
 Therapeutic Aspects, (1975), Marijuana and Health, Fifth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 118-119.
 Therapeutic Aspects, (1975), Marijuana and Health, Fifth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 117; Grinspoon, Lester and Bakalar, James, "Marihuana as Medicine," The Journal of the American Medical Association, vol. 273, No. 23, 1875-1876.
 Therapeutic Aspects, (1974), Marijuana and Health, Fourth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 134 citing; O'Shaughnessey, W.B, "On the preparation on the Indian hemp or gunjah," Translations of Medicine, Physiology and Sociology, Begal: 1838- 1840, pp. 71-102; 1842, pp. 421-46; and Moreau de Tours, K., "Psychotic depression with stupor: tendency toward dementia: treatment with an extract of cannabis indica," Lancette Hospital Gazette, 30:391 (1857).
 Therapeutic Aspects, (1975), Marijuana and Health, Fifth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 117.
 Mechoulam, S., Lander, N., Dikstein, S., Carlini E.A., and Blumenthal, M., (1976), "On the Therapeutic Possibilities of Some Cannabinoids," The Therapeutic Potential of Marihuana, (Cohen and Stillman eds.), 36.
 The California Research Advisory Panel (CRAP) described their research as "a large collaborative Phase III trial." In describing Phase III research, the final phase before market approval, the California Research Advisory Panel stated:
Among the safeguards for developing an investigational new drug is a step-wise testing process: the drug is tested in animals before humans, in normal volunteers before patients, and in small groups of people before large groups. Preclinical refers to non-human experiments, e.g., toxicity and pharmacology experiments in animals. Phase I is conducted in small numbers of normal human volunteers to determine dosage levels and other pharmacologic parameter. Phase II clinical trials typically involve small numbers of patients and comparisons to other treatment. Phase III is to confirm effectiveness and to assess adverse effects in a large and diverse population. Phase IV is used to describe post-marketing reporting on drug safety and effectiveness. Eleventh Annual Report for 1980 to the Governor and Legislature, CRAP, San Francisco, 1981 at 5.
The New York State Department of Health stated that "[t]he program is a large scale (phase III) cooperative clinical trial ..." see: "Evaluation of the Antiemetic Properties of Inhalation Marijuana in Cancer Patients Receiving Chemotherapy Treatment," New York State Department of Health, Office of Public Health, Chapter 810, Laws of 1980 Article 33-A, Public Health Law, September, 1981, at 3 cited in Randall, R.C. (editor), Marijuana, Medicine and the Law Volume II, Galen Press, 1989, page 47. For further discussion see footnote 23.
 Doblin, R., Kleiman, M., "Marijuana as antiemetic medicine: A survey of oncologists' experience and attitudes," J. Clin. Oncology 9 (1991): 7, 1314-1319.
 Almost all of the materials published in this compilation were part of the record of proceedings challenging the scheduling of marijuana under the Controlled Substances Act before the U.S. Drug Enforcement Administration. In the Matter of Marijuana Rescheduling Petition, No. 86-22 (U.S. Department of Justice, Drug Enforcement Administration, Sept. 6, 1988). Most of the materials were compiled by the Alliance for Cannabis Therapeutics led by Robert Randall and Alice O'Leary. Also included in this compilation are materials contained in the evidence submitted by the U.S. Drug Enforcement Administration. Finally, some of the materials included were published after that litigation was completed.
 Abrams, D., (1995), "Marijuana, the AIDS Wasting Syndrome, and the U.S. Government" (Response to Letter), New England Journal of Medicine, Vol. 333 (10): 670-671; Grinspoon, L, J, and Doblin, R., (1995), "Marijuana, the AIDS Wasting Syndrome, and the U.S. Government" (Letter to ed.), New England Journal of Medicine, Vol. 333 (10): 670-671.
 Plasse, T.F., Gorter, R.W., Krasnow, S.H., et al., "Recent clinical experience with dronabinol," Pharmacology, Biochemistry and Behavior 40 (1991): 695-700.
 Wesner, B., (1996), "The Medical Marijuana Issue Among PWAs: Reports of Therapeutic Use and Attitudes Toward Legal Reform," Drug Research Unit, Social Science Research Institute, University of Hawaii at Manoa.
 "Dope Use Improves Lives of Patients: Research," The Canberra Times, January 15, 1997.
 Hepler, R. and Frank, I., (1971), "Marijuana smoking and intraocular pressure," JAMA, 217: 1932; Hepler, R., Frank, I. and Ungerleider, J., (1972), "Pupillary constriction after marijuana smoking," American Journal of Ophthalmology, 74: 1185-1190; Hepler, R. and Petrus, R., (1976), "Experiences with administration of marijuana to glaucoma," The Therapeutic Potential of Marijuana, (Cohen and Stillman, eds.), 63-75; Goldberg, I., Kass, M. and Becker, B., (1978-1979), "Marijuana as a treatment for glaucoma," Sightsaving Review, (Winter issue): 147- 154; Merritt, J., Crawford, W., Alexander, P., Anduze, A. and Gelbart, S., (1980), "Effect of marihuana on intraocular and blood pressure in glaucoma," Ophthalmology, 87: 222-228; Zimmerman, T., (1980), "Efficacy in glaucoma treatment -- the potential of marijuana," Annals of Ophthalmology, 449-450.
 Carlini, E., Leite, J., Tannhauser, M. and Berardi, A, (1973), "Cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents," Journal Pharm. Pharmac., 25: 664-665; Dunn, M. and Davis, R., (1974), "The perceived effects of marijuana on spinal cord injured males," Paraplegia, 12: 175; Consroe, P., Wood, G. and Buchsbaum, H., (1975), "Anticonvulsant nature of marijuana smoking," JAMA, 234, 306-307; Feeney, D.M., "Marihuana and epilepsy: paradoxical anticonvulsant and convulsant effects," Marijuana Biological Effects: Analysis, Metabolism, Cellular Responses, Reproduction and the Brain, (Nahas, GG., Paxton, M., Bruade, J.C., Hardillier, and Harvey, D.J. eds.), Pergamon Press, Oxford, England, 643-657; Petro, D., (1980), "Marihuana as a therapeutic agent for muscle spasm of spasticity," Psychosomatics, 21: 81, 85; Cannabis, (1986), Therapeutic Claims in Multiple Sclerosis, Int'l Federation of Multiple Sclerosis Societies, 226.
 "The Lynn Pierson Therapeutic Research Program," Behavioral Health Sciences Division, Health and Environment Department, (March 1983 and 1984).
 "Michigan Department of Public Health Marijuana Therapeutic Research Project, Trial A 1980-1981," Department of Social Oncology, Evaluation Unit, Michigan Cancer Foundation (March 18, 1982).
 "Annual Report: Evaluation of Marijuana and Tetrahydrocannabinol in the Treatment of Nausea and/or Vomiting Associated with Cancer Therapy Unresponsive to Convention Anti- Emetic Therapy: Efficacy and Toxicity," Board of Pharmacy, State of Tennessee, (July 1983).
 See footnote 12.
 The results of this study were published at: Vinciguerra et al., "Inhalation Marijuana as an Antiemetic for Cancer Therapy," The New York State Journal of Medicine, pgs., 525-527, (October 1988).
 Kutner, Michael H., "Evaluation of the Use of Both Marijuana and THC in Cancer Patients for the Relief of Nausea and Vomiting Associated with Cancer Chemotherapy After Failure of Conventional Anti-Emetic Therapy: Efficacy and Toxicity" as prepared for the Composite State Board of Medical Examiners, Georgia Department of Health, by physicians and researchers at Emory University, Atlanta, (January 20, 1983).
 See footnote 12.
 Annual Reports of the California Research Advisory Panel submitted to the Governor and Legislature from 1981 (Twelfth Annual Report) to 1989 (Twentieth Annual Report).
 47 Fed. Reg. 10082, column 3. The FDA also note, "The risks to the public health from illicit use of THC are likely to be similar to marihuana." 47 Fed. Reg. 10083, column 2.
 Chang et al., "Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High Dose Methotrexate," Annals of Internal Medicine, Volume 91, Number 6, pg. 823, (December 1979).
 Statement Released by Barry R. McCaffrey, Director of the Office of National Drug Control Policy, The Administration's Response to the Passage of California Proposition 215 and Arizona Proposition 200, December 30, 1996, page 4 where it states:
HHS to ensure the protection of the public health will: (a) examine all medical and scientific evidence relevant to the perceived medical usefulness of marijuana; (b) identify gaps in knowledge and research regarding the health effects of marijuana; (c) determine whether further research or scientific evaluation could answer these questions; and (d) determine how that research could be designed and conducted to yield scientifically useful results.